Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial | Adolescent Medicine | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
Audio Author Interview (9:54)
1x
0:00 / 0:00
1.
Libman  IM, Pietropaolo  M, Arslanian  SA, LaPorte  RE, Becker  DJ.  Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes.  Diabetes Care. 2003;26(10):2871-2875.PubMedGoogle ScholarCrossref
2.
DuBose  SN, Hermann  JM, Tamborlane  WV,  et al Obesity in youth with type 1 diabetes in Germany, Austria, and the United States.  J Pediatr. 2015;167(3):627-632e4-4.PubMedGoogle ScholarCrossref
3.
Amiel  SA, Sherwin  RS, Simonson  DC, Lauritano  AA, Tamborlane  WV.  Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes.  N Engl J Med. 1986;315(4):215-219.PubMedGoogle ScholarCrossref
4.
Bjornstad  P, Snell-Bergeon  JK, Nadeau  KJ, Maahs  DM.  Insulin sensitivity and complications in type 1 diabetes: new insights.  World J Diabetes. 2015;6(1):8-16.PubMedGoogle ScholarCrossref
5.
Cleland  SJ, Fisher  BM, Colhoun  HM, Sattar  N, Petrie  JR.  Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?  Diabetologia. 2013;56(7):1462-1470.PubMedGoogle ScholarCrossref
6.
Nadeau  KJ, Regensteiner  JG, Bauer  TA,  et al.  Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.  J Clin Endocrinol Metab. 2010;95(2):513-521.PubMedGoogle ScholarCrossref
7.
Schauer  IE, Snell-Bergeon  JK, Bergman  BC,  et al.  Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study.  Diabetes. 2011;60(1):306-314.PubMedGoogle ScholarCrossref
8.
Specht  BJ, Wadwa  RP, Snell-Bergeon  JK, Nadeau  KJ, Bishop  FK, Maahs  DM.  Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes.  J Pediatr. 2013;162(2):297-301.PubMedGoogle ScholarCrossref
9.
Wiernsperger  NF, Bailey  CJ.  The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.  Drugs. 1999;58(suppl 1):31-39.PubMedGoogle ScholarCrossref
10.
Vella  S, Buetow  L, Royle  P, Livingstone  S, Colhoun  HM, Petrie  JR.  The use of metformin in type 1 diabetes: a systematic review of efficacy.  Diabetologia. 2010;53(5):809-820.PubMedGoogle ScholarCrossref
11.
Hamilton  J, Cummings  E, Zdravkovic  V, Finegood  D, Daneman  D.  Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.  Diabetes Care. 2003;26(1):138-143.PubMedGoogle ScholarCrossref
12.
Nadeau  KJ, Chow  K, Alam  S,  et al.  Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study.  Pediatr Diabetes. 2015;16(3):196-203.PubMedGoogle ScholarCrossref
13.
Nwosu  BU, Maranda  L, Cullen  K,  et al.  A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes.  PLoS One. 2015;10(9):e0137525.PubMedGoogle ScholarCrossref
14.
Särnblad  S, Kroon  M, Aman  J.  Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity.  Eur J Endocrinol. 2003;149(4):323-329.PubMedGoogle ScholarCrossref
15.
Centers for Disease Control and Prevention.  CDC growth charts: United States.2000. http://www.cdc.gov/growthcharts/charts.htm. Accessed October 5, 2015.
16.
The Diabetes Control and Complications Trial Research Group.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;329(14):977-986.PubMedGoogle ScholarCrossref
17.
Little  RJA, Rubin  DB.  Statistical Analysis With Missing Data. Hoboken, NJ: Wiley; 1987.
18.
Lund  SS, Tarnow  L, Astrup  AS,  et al.  Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control:. a randomized study.  PLoS One. 2008;3(10):e3363.PubMedGoogle ScholarCrossref
19.
Lund  SS, Tarnow  L, Astrup  AS,  et al.  Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.  Diabetes Obes Metab. 2009;11(10):966-977.PubMedGoogle ScholarCrossref
Original Investigation
December 1, 2015

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial

Author Affiliations
  • 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
  • 2Jaeb Center for Health Research, Tampa, Florida
  • 3Indiana University School of Medicine, Indianapolis
  • 4University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York
  • 5Joslin Diabetes Center, Boston, Massachusetts
  • 6Stanford University School of Medicine, Stanford, California
  • 7Vanderbilt University, Nashville, Tennessee
  • 8University of Florida, Gainesville
  • 9Children’s Mercy Hospital, Kansas City, Missouri
  • 10Yale University, New Haven, Connecticut
  • 11University of Iowa, Iowa City
  • 12University of Colorado, Anschutz Medical Campus, Aurora
JAMA. 2015;314(21):2241-2250. doi:10.1001/jama.2015.16174
Abstract

Importance  Previous studies assessing the effect of metformin on glycemic control in adolescents with type 1 diabetes have produced inconclusive results.

Objective  To assess the efficacy and safety of metformin as an adjunct to insulin in treating overweight adolescents with type 1 diabetes.

Design, Setting, and Participants  Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled randomized clinical trial involving 140 adolescents aged 12.1 to 19.6 years (mean [SD] 15.3 [1.7] years) with mean type 1 diabetes duration 7.0 (3.3) years, mean body mass index (BMI) 94th (4) percentile, mean total daily insulin 1.1 (0.2) U/kg, and mean HbA1c 8.8% (0.7%).

Interventions  Randomization to receive metformin (n = 71) (≤2000 mg/d) or placebo (n = 69).

Main Outcomes and Measures  Primary outcome was change in HbA1c from baseline to 26 weeks adjusted for baseline HbA1c. Secondary outcomes included change in blinded continuous glucose monitor indices, total daily insulin, BMI, waist circumference, body composition, blood pressure, and lipids.

Results  Between October 2013 and February 2014, 140 participants were enrolled. Baseline HbA1c was 8.8% in each group. At 13-week follow-up, reduction in HbA1c was greater with metformin (−0.2%) than placebo (0.1%; mean difference, −0.3% [95% CI, −0.6% to 0.0%]; P = .02). However, this differential effect was not sustained at 26-week follow up when mean change in HbA1c from baseline was 0.2% in each group (mean difference, 0% [95% CI, −0.3% to 0.3%]; P = .92). At 26-week follow-up, total daily insulin per kg of body weight was reduced by at least 25% from baseline among 23% (16) of participants in the metformin group vs 1% (1) of participants in the placebo group (mean difference, 21% [95% CI, 11% to 32%]; P = .003), and 24% (17) of participants in the metformin group and 7% (5) of participants in the placebo group had a reduction in BMI z score of 10% or greater from baseline to 26 weeks (mean difference, 17% [95% CI, 5% to 29%]; P = .01). Gastrointestinal adverse events were reported by more participants in the metformin group than in the placebo group (mean difference, 36% [95% CI, 19% to 51%]; P < .001).

Conclusions and Relevance  Among overweight adolescents with type 1 diabetes, the addition of metformin to insulin did not improve glycemic control after 6 months. Of multiple secondary end points, findings favored metformin only for insulin dose and measures of adiposity; conversely, use of metformin resulted in an increased risk for gastrointestinal adverse events. These results do not support prescribing metformin to overweight adolescents with type 1 diabetes to improve glycemic control.

Trial Registration  clinicaltrials.org Identifier: NCT01881828

×